Thus, restoring BBB through regulation of neurovascular pathways, such as targeting at LRP1 and phosphatidylinositol-binding clathrin assembly protein (PICALM) etc., has gained much attention for a potential therapeutic strategy for AD therapy 21. Here, LRP1 is linked to Alzheimer disease.